Additional file 2 of A new risk model based on a 11-m6A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer
Our aim was to evaluate the expression of chemokines in breast cancers before treatment to identify a molecular signature that could distinguish between women with or without cancer. We identified a p
Additional file 2. Expected ESR1-CCDC170 fusion products. In blue are shown the expected sizes of fusion products while in violet are depicted aspecific products, which can be generated during RT-qPCR
